What is HURA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.12B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HURA?

P/E (TTM) is n/a and 52-week range is $0.41 to $3.43 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HURA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HURA?

The company profile lists net income (TTM) near $-34M, EPS (TTM) near $-0.54 when available from the market-data feed. Figures are informational and may lag live markets.

Does HURA show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.00, yield near 0.01% when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is TuHURA Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Tampa, Florida, US, 63.7M shares outstanding, ISIN US8989201038 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

TuHURA Biosciences Inc

$HURA

Health Care · Biotechnology

IR Run Scenarios

$1.96

+1.55%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 22 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Employees

Website

tuhurabio.com/

IPO

2016-07-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)